Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series
IntroductionEfgartigimod is effective and well-tolerated in patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG). However, the therapeutic potential and the safety profile of efgartigimod in myasthenic crisis (MC) remained largely unknown.MethodsThis...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2024-07-01
|
| Серии: | Frontiers in Immunology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1418503/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
